Evidence map›Paper›PMID 39748380›Full record

ArticleCardiovascular diabetology2025

Deep-learning prediction of cardiovascular outcomes from routine retinal images in individuals with type 2 diabetes.

Mohammad Ghouse Syed, Emanuele Trucco, Muthu R K Mookiah, Chim C Lang, Rory J McCrimmon, Colin N A Palmer, Ewan R Pearson, Alex S F Doney, Ify R Mordi

Abstract readComparative StudyValidation Study
In one paragraph

Article in Cardiovascular diabetology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mohammad Ghouse SyedVAMPIRE project, Computing, School of Science and Engineering, University of Dundee, Dundee, USA.
Emanuele TruccoVAMPIRE project, Computing, School of Science and Engineering, University of Dundee, Dundee, USA.
Muthu R K MookiahVAMPIRE project, Computing, School of Science and Engineering, University of Dundee, Dundee, USA.
Chim C LangDivision of Cardiovascular Research, School of Medicine, University of Dundee, Dundee, DD1 9SY, UK.
Rory J McCrimmonDivision of Systems Medicine, School of Medicine, University of Dundee, Dundee, UK.
Colin N A PalmerDivision of Population Health and Genomics, School of Medicine, University of Dundee, Dundee, UK.
Ewan R PearsonDivision of Population Health and Genomics, School of Medicine, University of Dundee, Dundee, UK.
Alex S F DoneyDivision of Cardiovascular Research, School of Medicine, University of Dundee, Dundee, DD1 9SY, UK.
Ify R MordiDivision of Cardiovascular Research, School of Medicine, University of Dundee, Dundee, DD1 9SY, UK. i.mordi@dundee.ac.uk.

Funding

British Heart Foundation FS/ICRF/24/26101National Institute for Health and Care Research 16/136/102
6 · The paper itself

Abstract

backgroundPrior studies have demonstrated an association between retinal vascular features and cardiovascular disease (CVD), however most studies have only evaluated a few simple parameters at a time. Our aim was to determine whether a deep-learning artificial intelligence (AI) model could be used to predict CVD outcomes from routinely obtained diabetic retinal screening photographs and to compare its performance to a traditional clinical CVD risk score.

methodsWe included 6127 individuals with type 2 diabetes without myocardial infarction or stroke prior to study entry. The cohort was divided into training (70%), validation (10%) and testing (20%) cohorts. Clinical 10-year CVD risk was calculated using the pooled cohort equation (PCE) risk score. A polygenic risk score (PRS) for coronary heart disease was also obtained. Retinal images were analysed using an EfficientNet-B2 network to predict 10-year CVD risk. The primary outcome was time to first major adverse CV event (MACE) including CV death, myocardial infarction or stroke.

results1241 individuals were included in the test cohort (mean PCE 10-year CVD risk 35%). There was a strong correlation between retinal predicted CVD risk and the PCE risk score (r = 0.66) but not the polygenic risk score (r = 0.05). There were 288 MACE events. Higher retina-predicted risk was significantly associated with increased 10-year risk of MACE (HR 1.05 per 1% increase; 95% CI 1.04-1.06, p < 0.001) and remained so after adjustment for the PCE and polygenic risk score (HR 1.03; 95% CI 1.02-1.04, p < 0.001). The retinal risk score had similar performance to the PCE (both AUC 0.697) and when combined with the PCE and polygenic risk score had significantly improved performance compared to the PCE alone (AUC 0.728). An increase in retinal-predicted risk within 3 years was associated with subsequent increased MACE likelihood.

conclusionsA deep-learning AI model could accurately predict MACE from routine retinal screening photographs with a comparable performance to traditional clinical risk assessment in a diabetic cohort. Combining the AI-derived retinal risk prediction with a coronary heart disease polygenic risk score improved risk prediction. AI retinal assessment might allow a one-stop CVD risk assessment at routine retinal screening.

Indexed as

Cardiovascular DiseasesDeep LearningDiabetes Mellitus, Type 2Diabetic RetinopathyPredictive Value of TestsAgedDecision Support TechniquesFemaleHeart Disease Risk FactorsHumansImage Interpretation, Computer-AssistedMaleMiddle AgedPhotographyPrognosisReproducibility of ResultsArtificial intelligenceCardiovascular riskDiabetesRetina

Identifiers

PMID39748380
PMCPMC11697721

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.